Amphastar Pharmaceuticals, Inc.
AMPH · NASDAQ Global Select · USD
29,38USD
+0,89 (+3,12 %)Stand 9. Nov., 21:00
Nachbörslich29,380,00 (0,00 %)19:30 ET
Kennzahlen
- Eröffnung
- 28,74
- Vortag
- 28,49
- Tagesspanne
- 28,50 – 29,70
- 52 Wochen
- 16,65 – 31,00
- Volumen
- 635.799
- Ø Volumen
- 459.448
- Börsenwert
- 1,25 Mrd. $
- KGV
- 13,1
- Gewinn je Aktie (TTM)
- 2,19
- Dividendenrendite
- 0,0 %
- Beta
- 0,9
- Nächste Zahlen
- 25. Feb. 2027
Finanzen
| USD | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 719,89 Mio. | 731,97 Mio. | 644,4 Mio. | 498,99 Mio. | 437,77 Mio. |
| Herstellungskosten | 363,83 Mio. | 358,11 Mio. | 293,27 Mio. | 250,13 Mio. | 238,03 Mio. |
| Bruttogewinn | 356,06 Mio. | 373,86 Mio. | 351,12 Mio. | 248,86 Mio. | 199,74 Mio. |
| Forschung und Entwicklung | 85,84 Mio. | 73,91 Mio. | 73,74 Mio. | 74,77 Mio. | 60,93 Mio. |
| Vertrieb und Verwaltung | 129,81 Mio. | 94,52 Mio. | 80,39 Mio. | 66,59 Mio. | 68,92 Mio. |
| Operatives Ergebnis | 140,4 Mio. | 205,42 Mio. | 196,99 Mio. | 107,5 Mio. | 69,89 Mio. |
| EBITDA | 212,31 Mio. | 277,31 Mio. | 240,29 Mio. | 146,16 Mio. | 110,49 Mio. |
| Nettogewinn | 98,09 Mio. | 159,52 Mio. | 137,55 Mio. | 91,39 Mio. | 62,12 Mio. |
| Gewinn je Aktie (verwässert) | 2,03 | 3,06 | 2,60 | 1,74 | 1,25 |
Umsatz nach Segment
Produkte · FY 2025
- Epinephrine70,64 Mio. $100,00 %
Anteil · ggü. Vorjahr (FY 2024)
Regionen · FY 2025
- UNITED STATES681,42 Mio. $94,66 %−3,71 %
- France35,28 Mio. $4,90 %
- China3,18 Mio. $0,44 %
Anteil · ggü. Vorjahr (FY 2024)
Bewertung
Letzte 12 Monate
- KGV
- 13,1
- Kurs-Umsatz-Verhältnis
- 1,7
- Kurs-Buchwert-Verhältnis
- 1,5
- PEG
- -3,1
- Bruttomarge
- 46,8 %
- Operative Marge
- 18,7 %
- Nettomarge
- 13,3 %
- Verschuldungsgrad
- 0,8
- EV/EBITDA
- 7,9
- Eigenkapitalrendite
- 12,6 %
- Kapitalrendite (ROIC)
- 6,9 %
- Free-Cashflow-Rendite
- 11,1 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 49,5 % | 51,1 % | 54,5 % | 49,9 % | 45,6 % |
| Operative Marge | 19,5 % | 28,1 % | 30,6 % | 21,5 % | 16,0 % |
| Nettomarge | 13,6 % | 21,8 % | 21,3 % | 18,3 % | 14,2 % |
| KGV | 12,8 | 11,3 | 21,7 | 14,9 | 17,9 |
| Kurs-Umsatz-Verhältnis | 1,7 | 2,5 | 4,6 | 2,7 | 2,5 |
| Kurs-Buchwert-Verhältnis | 1,6 | 2,5 | 4,7 | 2,6 | 2,5 |
| Verschuldungsgrad | 0,8 | 0,9 | 1,0 | 0,2 | 0,2 |
| Liquidität 3. Grades | 4,0 | 3,1 | 2,2 | 4,0 | 3,1 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | 1,74 Mrd. | 2,3 Mrd. | 3,46 Mrd. | 1,31 Mrd. | 1,09 Mrd. |
| EV/EBITDA | 8,2 | 8,3 | 14,4 | 8,9 | 9,9 |
| Eigenkapitalrendite | 12,4 % | 21,8 % | 21,5 % | 17,3 % | 13,9 % |
| Kapitalrendite (ROIC) | 7,5 % | 12,3 % | 12,4 % | 13,1 % | 9,2 % |
| Free-Cashflow-Rendite | 9,7 % | 9,6 % | 4,9 % | 4,8 % | 6,3 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | −1,7 % | +13,6 % | +29,1 % | +14,0 % | +25,1 % |
| Bruttogewinn | −4,8 % | +6,5 % | +41,1 % | +24,6 % | +39,3 % |
| Operatives Ergebnis | −31,7 % | +4,3 % | +83,2 % | +53,8 % | +538,0 % |
| Nettogewinn | −38,5 % | +16,0 % | +50,5 % | +47,1 % | +4.327,4 % |
| Gewinn je Aktie | −33,7 % | +17,7 % | +49,4 % | +39,2 % | +4.270,6 % |
| Freier Cashflow | −29,7 % | +18,6 % | +123,1 % | −7,6 % | +201,3 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen · Hold
- 0Stark kaufen
- 3Kaufen
- 8Halten
- 1Verkaufen
- 0Stark verkaufen
Kursziel
21,00
Durchschnitt · −28,52 %
Schätzungen
| FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|
| Umsatz (Ø) | 758,48 Mio. | 792,44 Mio. | 817,7 Mio. |
| Umsatz (Tief – Hoch) | 731,61 Mio. – 785,33 Mio. | 757,14 Mio. – 827,75 Mio. | 756,26 Mio. – 854 Mio. |
| Gewinn je Aktie (Ø) | 3,20 | 3,35 | 3,59 |
| Gewinn je Aktie (Tief – Hoch) | 3,00 – 3,53 | 3,10 – 3,72 | 3,31 – 3,79 |
| Analysten | 3 | 2 | 1 |
Letzte Änderungen
- Wells Fargo6. Nov. 2026Equal Weight
- Barclays18. Aug. 2026Equal Weight
- Piper Sandler7. Aug. 2026Neutral
- Wells Fargo7. Aug. 2026Equal Weight
- B of A Securities29. Juni 2026Neutral → Underperform
- Barclays3. Juni 2026Equal Weight
- Wells Fargo14. Mai 2026Overweight → Equal Weight
- Piper Sandler11. Mai 2026Neutral
Quartalszahlen
Nächste Zahlen: 25. Feb. 2027| Nov. 2026 | Aug. 2026 | Mai 2026 | Feb. 2026 | Nov. 2025 | Aug. 2025 | Mai 2025 | Feb. 2025 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | 0,86 | 0,62 | 0,70 | 0,90 | 0,77 | 0,71 | 0,66 | 1,01 |
| Gewinn je Aktie · Tatsächlich | 1,14 | 0,91 | 0,42 | 0,73 | 0,93 | 0,85 | 0,74 | 0,92 |
| Abweichung | +32,71 % | +46,77 % | −40,00 % | −19,16 % | +20,78 % | +19,72 % | +12,12 % | −8,91 % |
| Umsatz · Tatsächlich | 207,61 Mio. | 183,9 Mio. | 171,17 Mio. | 183,11 Mio. | 191,84 Mio. | 174,41 Mio. | 170,53 Mio. | 186,52 Mio. |
Dividenden und Splits
| Ex-Tag | Zahltag | Betrag |
|---|---|---|
| 11. Juni 2010 | 30. Juni 2010 | 0,30 |
| 11. Juni 2009 | 30. Juni 2009 | 0,30 |
Aktiensplits
–
Eigentümer
Institutionen
Q2 2026 · 13F
- Anteil institutioneller Investoren
- 63,19 %
- Investoren mit 13F-Meldung
- 215
Größte Investoren
- BLACKROCK, INC.11,97 %5,22 Mio.
- DIMENSIONAL FUND ADVISORS LP5,28 %2,31 Mio.
- STATE STREET CORP3,62 %1,64 Mio.
- VANGUARD CAPITAL MANAGEMENT LLC3,40 %1,48 Mio.
- AMERICAN CENTURY COMPANIES INC2,70 %1,18 Mio.
- MARSHALL WACE, LLP2,44 %1,07 Mio.
- GEODE CAPITAL MANAGEMENT, LLC2,22 %969.840
- FULLER & THALER ASSET MANAGEMENT, INC.2,18 %949.238
Insider-Geschäfte
- PETERS WILLIAM J5. Nov. 2026 · director, officer: CFO, EVP & TREASURERKauf11.000 Aktien · 17,99
- PETERS WILLIAM J5. Nov. 2026 · director, officer: CFO, EVP & TREASURERVerkauf12.631 Aktien · 28,99
- PETERS WILLIAM J5. Nov. 2026 · director, officer: CFO, EVP & TREASURERVerkauf11.000 Aktien · 17,99
- PETERS WILLIAM J4. Nov. 2026 · director, officer: CFO, EVP & TREASURERKauf16.000 Aktien · 13,03
- PETERS WILLIAM J4. Nov. 2026 · director, officer: CFO, EVP & TREASURERVerkauf16.000 Aktien · 28,03
- PETERS WILLIAM J4. Nov. 2026 · director, officer: CFO, EVP & TREASURERVerkauf16.000 Aktien · 13,03
- PETERS WILLIAM J21. Sept. 2026 · director, officer: CFO, EVP & TREASURERVerkauf4139 Aktien · 25,00
- Zhou Rong16. Sept. 2026 · officer: SENIOR EVP, PRODUCTION CENTERKauf10.000 Aktien · 13,35
Vergleichbare Unternehmen
AMRXAmneal Pharmaceuticals, Inc.21,28+5,66 %
AYTUAytu BioPharma, Inc.1,79−2,19 %
BHCBausch Health Companies Inc.8,40+2,63 %
COLLCollegium Pharmaceutical, Inc.24,71+2,07 %
CPHIChina Pharma Holdings, Inc.0,565−0,86 %
ETONEton Pharmaceuticals, Inc.64,35+13,97 %
RDYDr. Reddy's Laboratories Limited15,05+0,97 %
TEVATeva Pharmaceutical Industries Limited42,97+0,84 %
Über das Unternehmen
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
Führung
- Yongfeng ZhangCo-Founder, President, Chief Executive Officer, Chief Scientific Officer & Director
- Ziping LuoChairman of the Board, Chief Scientist & Chief Operating Officer
- William J. PetersChief Financial Officer, Executive Vice President of Finance, Treasurer & Director
- Rong ZhouSenior EVice President of Production & EVP of Scientific Affairs
- Jacob LiawatidewiExecutive Vice President of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director
- Tony MarrsExecutive Vice President of Regulatory Affairs & Clinical Operations
- CEO
- Yongfeng Zhang
- Mitarbeitende
- 1.976
- Hauptsitz
- Rancho Cucamonga, CA, US
- Sektor
- Healthcare
- Branche
- Drug Manufacturers - Specialty & Generic
- Börsengang
- 25. Juni 2014
- Website
- amphastar.com
Nachrichten
- Seeking Alpha · 6. Nov., 18:04Amphastar Pharmaceuticals, Inc. (AMPH) Q3 2026 Earnings Call Transcript
- Zacks Investment Research · 5. Nov., 19:31Amphastar (AMPH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
- MarketBeat · 5. Nov., 19:15Amphastar Pharmaceuticals Q3 Earnings Call Highlights
- Zacks Investment Research · 5. Nov., 18:46Amphastar Pharmaceuticals (AMPH) Tops Q3 Earnings and Revenue Estimates
- PRNewsWire · 5. Nov., 16:10Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026
- Zacks Investment Research · 29. Okt., 11:06Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
- PRNewsWire · 29. Okt., 6:00Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 5, 2026
- Zacks Investment Research · 6. Okt., 10:41Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?
- Defense World · 6. Okt., 10:14Comparing Enanta Pharmaceuticals (NASDAQ:ENTA) and Amphastar Pharmaceuticals (NASDAQ:AMPH)
- Defense World · 30. Sept., 6:28Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Average Rating of “Reduce” from Analysts
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.